nagilactone C
norditerpene lactone isolated from leaves of Podocarpus; structure
Also Known As:
nagilactone A of nagilactone C; nagilactone B of nagilactone C; nagilactone D of nagilactone C; nagilactone E of nagilactone C; nagilactone F of nagilactone C
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Ho, Hsiu-O:
1 article
(04/2008)
|
2. | Hwang, Shy-Yuan:
1 article
(04/2008)
|
3. | Kuo, Yao-Haur:
1 article
(04/2008)
|
4. | Kuo, Yu-Jen:
1 article
(04/2008)
|
5. | Liang, Yu-Han:
1 article
(04/2008)
|
6. | Liao, Chia-Ching:
1 article
(04/2008)
|
7. | Wu, Ming-Der:
1 article
(04/2008)
|
8. | Banskota, A H:
1 article
(11/2001)
|
9. | Gewali, M B:
1 article
(11/2001)
|
10. | Kodata, S:
1 article
(11/2001)
|
Related Diseases
1. | Carcinoma (Carcinomatosis)
04/01/2008
- " Of these isolates, nagilactone C (2) showed the most significant inhibitory effects against DLD cells (human colon carcinoma) (ED(50)=2.57 microg/ml) and compounds 7, 8, 10, 11, and 12 had moderate cytotoxic activity against human KB (human oral epithelium carcinoma), Hela (human cervical carcinoma), Hepa (human hepatoma), DLD (colon carcinoma), and A-549 (human lung carcinoma) tumor cell lines. " 11/01/2001
- " Nagilactone C possessed potent antiproliferative activity against human fibrosarcoma and murine colon carcinoma tumor cell lines exhibiting ED50 values of 2.3 and 1.2 microg/ml, respectively. "
|
2. | Hepatocellular Carcinoma (Hepatoma)
|
3. | Fibrosarcoma
|
|